Evaluation of cancer drug infusion devices prior to the implementation of a compounding robot. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Journal of Oncology Pharmacy Practice Année : 2023

Evaluation of cancer drug infusion devices prior to the implementation of a compounding robot.

Résumé

Introduction Compounding robots are increasingly being implemented in hospital pharmacies. In our hospital, the recent acquisition of a robot (RIVATM, ARxIUM) for intravenous cancer drug compounding obliged us to replace the previously used infusion devices. The objective of the present study was to assess and qualify the new intravenous sets prior to their use in our hospital and prior to the implementation of the compounding robot. Materials and Methods The ChemoLockTM (ICU Medical) was compared with the devices used previously for compounding (BD PhaSealTM, Becton-Dickinson) and infusion (Connect-ZTM, Codan Medical). The connection/disconnection of infusion devices to/from 50 mL infusion bags was tested with a dynamometer (Multitest-i, Mecmesin). Leakage contamination was visualized by a methylene blue assay and was quantified in simulated pump infusions with 20 mg/mL quinine sulfate (N = 36/group); after the analytical assay had been validated, quinine was detected by UV-spectrophotometry at 280 and 330 nm. Groups were compared using chi-squared or Mann–Whitney U tests. Results The connection/disconnection test showed that although all the devices complied with the current standard, there was a statistically significant difference in the mean ± standard deviation compression force (51.5 ± 11.6 for the Connect-ZTM vs. 60.3 ± 11.7 for the ChemoLockTM; p = 0.0005). Leaks were detected in 32 (29.1%) of the 110 tests of the ChemoLockTM. The contamination rates were also significantly different: 13.9% for the BD PhaSealTM versus 75.0% for the ChemoLockTM; p < 0.0001). Discussion/conclusion Our results showed that the new infusion device complied with current standards. However, the presence of contamination emphasizes the need for operators to use the recommended personal protective equipment. Further studies of contamination with cancer drugs are required.
Fichier non déposé

Dates et versions

hal-04143931 , version 1 (28-06-2023)

Identifiants

Citer

Guillaume Caron, Michele Vasseur, Justin Courtin, Morgane Masse, Bertrand Décaudin, et al.. Evaluation of cancer drug infusion devices prior to the implementation of a compounding robot.. Journal of Oncology Pharmacy Practice, 2023, Journal of Oncology Pharmacy Practice, pp.10781552231170792. ⟨10.1177/10781552231170792⟩. ⟨hal-04143931⟩

Collections

UNIV-LILLE
12 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More